Lexicon to Present Clinical Data for LX1031 and LX1032 at Digestive Disease Week

THE WOODLANDS, Texas, May 27 /PRNewswire-FirstCall/ --Lexicon Pharmaceuticals,
Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering and
developing breakthrough treatments for human disease, announced today that the
company will be giving oral presentations on two of its clinical-stage drug
development programs: LX1031, an oral drug candidate for the treatment of
irritable bowel syndrome (IBS), and LX1032, an oral drug candidate for
managing gastrointestinal symptoms associated with carcinoid syndrome. The
presentations will take place at Digestive Disease Week (DDW) in Chicago,
Illinois on Sunday, May 31 and Monday, June 1, respectively. DDW is the
world's largest gathering of physicians and researchers in the fields of
gastroenterology, hepatology, endoscopy and gastrointestinal surgery. LX1031
is currently in a Phase 2 clinical trial in patients with non-constipating
IBS, and LX1032 is entering a Phase 2 study in patients with carcinoid
syndrome.

For more information on these programs and to download both presentations
(available after June 1), please visit www.lexpharma.com.

About Lexicon
Lexicon is a biopharmaceutical company focused on discovering and developing
breakthrough treatments for human disease. Lexicon currently has five drug
candidates in development for autoimmune disease, carcinoid syndrome,
diabetes, glaucoma and irritable bowel syndrome, all of which were discovered
by the company's research team. The company has used its proprietary gene
knockout technology to identify more than 100 promising drug targets. Lexicon
has focused drug discovery efforts on these biologically-validated targets to
create its extensive pipeline of clinical and preclinical programs. For
additional information about Lexicon and its programs, please visit
www.lexpharma.com.

Safe Harbor Statement
This press release contains "forward-looking statements," including statements
relating to Lexicon's clinical development of LX1031 and LX1032 and the
potential therapeutic and commercial potential of LX1031 and LX1032. This
press release also contains forward-looking statements relating to Lexicon's
growth and future operating results, discovery and development of products,
strategic alliances and intellectual property, as well as other matters that
are not historical facts or information. All forward-looking statements are
based on management's current assumptions and expectations and involve risks,
uncertainties and other important factors, specifically including those
relating to Lexicon's ability to successfully conduct clinical development of
LX1031 and LX1032 and preclinical and clinical development of its other
potential drug candidates, advance additional candidates into preclinical and
clinical development, obtain necessary regulatory approvals, achieve its
operational objectives, obtain patent protection for its discoveries and
establish strategic alliances, as well as additional factors relating to
manufacturing, intellectual property rights, and the therapeutic or commercial
value of its drug candidates, that may cause Lexicon's actual results to be
materially different from any future results expressed or implied by such
forward-looking statements. Information identifying such important factors is
contained under "Factors Affecting Forward-Looking Statements" and "Risk
Factors" in Lexicon's annual report on Form 10-K for the year ended December
31, 2008, as filed with the Securities and Exchange Commission. Lexicon
undertakes no obligation to update or revise any such forward-looking
statements, whether as a result of new information, future events or
otherwise.

SOURCE Lexicon Pharmaceuticals, Inc.

Jason Ray, Manager, Corporate Communications and Investor Relations of Lexicon
Pharmaceuticals, Inc., +1-281-863-3225, jray@lexpharma.com